Evaluating the Therapeutic Success of Keloids Treated With Cryotherapy and Intralesional Corticosteroids Using Noninvasive Objective Measures by Schwaiger, Hannah et al.
Evaluating the Therapeutic Success of Keloids Treated
With Cryotherapy and Intralesional Corticosteroids Using
Noninvasive Objective Measures
Hannah Schwaiger, MD,* Markus Reinholz, MD,* Julian Poetschke, MD,
†
Thomas Ruzicka, MD,* and Gerd Gauglitz, MD, MMS*
BACKGROUND Intralesional corticosteroid injections combined with cryotherapy are considered a first-line
therapy for keloids. However, objective evaluation on its efficacy is widely missing.
OBJECTIVE In this study, the authors evaluated the therapeutic benefits of cryotherapy directly followed by
intralesional crystalline triamcinolone acetonide injections using ultrasound and a 3D topographic imaging
device.
MATERIALS AND METHODS Fifteen patients with keloids were treated with cryotherapy and intralesional
injections of triamcinolone acetonide for a total of 4 times at intervals of 4 weeks. Objective assessment was
performed at each visit.
RESULTS After the last treatment, a significant average reduction of scar volume of 34.3% and an average
decrease in scar height of 41.3% as determined by 3D imaging was observed compared with baseline.
Ultrasound revealed an average reduction of scar height of 31.7% and an average decrease in tissue pene-
tration depth of 37.8% when compared with baseline measurements.
CONCLUSION Objective measurements of relevant keloid characteristics as height, volume, and penetration
depth help in quantifying the therapeutic effect. The observed results confirm that intralesional injections of
crystalline triamcinolone acetonide combined with cryotherapy represent a powerful approach to reduce scar
height and volume significantly.
The authors have indicated no significant interest with commercial supporters.
Excessive scarring is aesthetically disturbing andfrequently represents a psychosocial burden for
affected patients.1 As keloids often go along with
pruritus, contractures, and pain, the need for
treatment is apparent and not solely based on cosmetic
reasoning.2 Keloids are benign hyperproliferations of
dermal connective tissue. Injury of the deep dermis
commonly results in scar formation. The physiologic
wound healing cascade consists of inflammation,
proliferation, and a remodeling phase.3–5 In
pathologic scar formation, a prolonged inflammatory
phase and some molecular alterations concerning
inflammatory pathways are held responsible for
excessive scarring.6,7 Keloids commonly appear on the
upper trunk, and, in contrast to hypertrophic scars,
whichmay show a similar appearance, they exceed the
margins of the original wound. Keloids can occur
spontaneously but often show a genetic
predisposition. Asian or African individuals are more
prone to develop keloids.8–11Usually, keloid treatment
remains more challenging compared with the therapy
of hypertrophic scars because keloids are associated
with a high recurrence rate and show no tendency to
regress spontaneously.2
Over the years, therapeutic approaches to treat
excessive scarring have significantly improved.12–14
Common therapeutic strategies include silicone gel
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sheeting, pressure therapy, radiation, and cryosur-
gery.15–17 New treatment options are intralesional
injections of 5-fluorouracil, interferon, and bleomycin
for therapy-refractory scars10,18,19 as well as
nonablative and ablative lasers.20,21 In clinical
practice, the injection of crystalline glucocorticoids
alone or in combination with cryotherapy represents
a well-proven therapy.15,22–24 Combinational
approaches seem to be superior25 than respective
monotherapies. It is assumed that cryotherapy induces
changes in microcirculation and apoptosis of
fibroblasts in treated scars.15 This procedure results in
a localized dermal edema, which facilitates injections
into the scar tissue as larger volumes can be applied
more easily, thus enhancing the therapeutic effect.13
Common side effects of cryotherapy are pain, a pro-
longed healing time because of the induced blistering,
and potential depigmentation.14 Triamcinolone
acetonide reduces scar thickness by inhibition of the
collagen biosynthesis and the proliferation of
fibroblasts. Potential side effects include atrophy of the
subcutis, the formation of telangiectasia, and
pigmentary alterations.2
To date, a variety of articles and studies to evaluate
different therapeutic approaches for excessive scarring
exist. However, most of them use rather subjective
measurements to document therapeutic improve-
ments of respective scar therapies. Nevertheless, over
the last decade, various studies have highlighted
ultrasound as anobjective tool to determine changes in
scar size.4,26–30More recently, the application of an 3D
topographic imaging devices (PRIMOSpico) has also
been studied in this context.31,32 Based on current data,
both tools seem reliable to deliver objective data on
changes of physical scar characteristics.27,33
Although combination of cryotherapy and intrale-
sional triamcinolone acetonide represents a frequently
used technique for the treatment of keloids and has
been highlighted as a promising approach in current
guidelines, only 4 studies exist on its combina-
tion.25,34–36 All of them confirmed the effectiveness of
intralesional corticosteroids combined with cryother-
apy, but none of them applied modern objective
measurement methods to assess the therapeutic
success. Furthermore, treatment regimens varied,
and patients were evaluated before and at the end of
treatment, without information on treatment prog-
ress. Other studies did not differentiate between
hypertrophic scars and keloids. In this study, the
authors therefore aimed to evaluate the therapeutic
outcome of the guideline-based combination of
cryotherapy and corticosteroid injections for keloid




Fifteen patients were included from the outpatient
scar clinic (7 women, 8 men) aged 18 to 54 years
(34.5 6 12.5 years) with medium-sized keloids, as
defined by common diagnostic criteria,2 which had
existed for an average of 7.8 years (65.3 years).
Fitzpatrick skin types ranged from II to IV. Keloids
either after trauma, surgery, acne, or by spontaneous
formation were located mainly on the upper trunk
(Table 1). Most patients had treatments in the past,
which mainly included moisturizers such as silicones,
cryotherapy alone, or laser, which were either unsuc-
cessful or led to a regress of keloid formation. The
patients were enrolled after approval by the Ethics
Committee of the Ludwig-Maximilian University, and
written informed consent from each patient was
obtained. Exclusion criteria were pregnancy, intrale-
sional injections of corticosteroids during the last 6
months, chronic diseases such as diabetes or coagu-
lopathies, and participation in other studies.
Patients were treated 4 timeswith cryotherapy directly
followed by intralesional injections of triamcinolone
acetonide into each scar at monthly intervals. Stan-
dardization of injection techniques was based on the
authors’ clinical settings and obtained by using the
same drug, same needle size (27 Gauge), and same
brand of Luer-lock syringes for injections. Keloids
were injected by the same experienced physician at
each visit. Injection volumes were depending on the
size of the keloid and were carefully documented;
a visible blanching of the keloid tissue was considered
as end points of injections. In accordance with other
studies, national and international guidelines
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treatment was initiated with triamcinolone acetonide
concentrations of 10mg/mL, which were increased up
to 40 mg/mL at subsequent visits.34,37 Directly before
injection, cryotherapy was applied with liquid nitro-
gen spray for 10 seconds and the exact same procedure
was repeated after 1 minute. Ultrasound and 3D
topographic imaging measurements were performed
directly before the respective treatment by the same
investigator.
3D Topographic Imaging Device: Phase Shift
Rapid In Vivo Measurement of
Skin (PRIMOSpico)
To provide 3-dimensional and high-resolution images
of the scars, the PRIMOSpico system (GFMesstechnik,
Teltow, Germany) was used. The device is commonly
applied to measure wrinkles.26,27,38 Furthermore, it is
highly suitable to assess pathologic scarring.32,33Using
micromirrors, this 3D topographic imaging device
projects a stripe pattern with sinusoidal gray levels,
which is captured by a CCD camera. Measuring the
gray levels and displacement of this stripe pattern
creates a detailed and color-coded height map of the
measured surface. These height maps were used to
analyze scar height and volume.
Sonography
Scars were assessed during each visit by using a high-
resolution B-image sonogram. To ensure a good
penetration depth into the scar combined with a high
resolution, a 11-MHz receiving transducerwas used in
combination with the Logiq P6 Pro (GE Healthcare,
Solingen, Germany) and a sufficient amount of ultra-
sound gel was applied to avoid pressure on the scar,
which may influence measurement. According to the
manufacturer, this configuration yields a skin pene-
trationdepth of up to 40mmanda lateral resolution of
about 158 mm. Sonography was used to analyze scar
elevation and cutaneous penetration.
Digital Photography
Digital photography was used to document the ther-
apeutic success. A professional in-house photographer
took photos during each visit after obtaining addi-
tional written informed consent for this procedure
from each patient. Photography was not standardized
between visits within the study limitations section.
Data Analysis
Statistical analyses were performed using the
GraphPad Prism 5 Software (GraphPad Software,
TABLE 1. Patient Characteristics







1 M 21 II Trauma Shoulder/back/
breast
1.5 2 None
2 M 48 III Surgery Breast 4 2 None
3 F 48 II Surgery Breast 10 2 Moisturizing,
silicone
4 M 34 IV Spontaneous Shoulder/arms 23 2 None
5 F 21 III Surgery Back/shoulder 2 2 Surgical excision
6 F 46 III Surgery Back/breast 7 2 Moisturizing
7 M 45 II Trauma Breast/shoulder 10 2 None
8 M 34 IV Spontaneous Breast 16 2 None
9 M 29 III Acne Back 4.5 2 Moisturizing,
cryotherapy
10 F 50 II Surgery Breast/shoulder 4 + Moisturizing
11 F 28 III Surgery Neck 2 + Moisturizing
12 M 54 II Surgery Breast 12 2 Moisturizing
13 F 20 III Acne Shoulder/back/
breast
5 + Moisturizing
14 F 18 III Spontaneous Shoulder 2 2 Moisturizing, laser
15 M 21 III Spontaneous Shoulder 2 2 Moisturizing
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Inc., La Jolla, CA). The data were first analyzed for
Gaussian distribution using the D’Agostino and
Pearson omnibus normality test. After establishing
Gaussian distribution of data, the repeated-measures
ANOVA was applied to calculate statistical
significance of the results, which were displayed as
mean 6 SD. To compare the results of each visit in
detail, Bonferroni’s Multiple Comparison Test was
used. The significance level was set at a = 0.05.
Results
The authors evaluated the therapeutic progress of
triamcinolone acetonide injections in combination
with cryotherapy in a total of 15 patients during each
visit directly before the respective treatment. In addi-
tion, adverse events and side effects were documented:
8 patients developed telangiectasia, 4 of them showed
pigmentation disorders such as reddish brown
discoloration of the keloid, and one suffered from
temporary ulceration after the fourth injection. The
obtained results regarding injected amount of
triamcinolone acetonide were evaluated for each visit
(Table 2). For the first and the second injection, the
amount of triamcinolone acetonide averaged 0.9 mL
(60.6 mL for the first injection and 60.7 mL for the
second injection) for each keloid and decreased to
0.4 mL (60.3 mL) of injected triamcinolone acetonide
at the third visit. At Visit 4, an average amount of
0.5 mL (60.3 mL) triamcinolone acetonide was
injected. The decreased amount of crystalline corti-
costeroid throughout the treatment session resulted
from the reduced scar volume.
Digital Photography
Visual assessment of photographs taken before and
after treatment showed clear improvement of scar
volume and circumference objectively interpreted by
a blinded rater (Figure 1).
3D Topographic Imaging Device
In matching mode, a program of the used 3D topo-
graphic imaging device, a comparison of the scar
before (Figure 2A) and after treatment (Figure 2B) is
possible. A highly significant (p < .0001) reduction of
surface height after 4 treatment sessions could be
observed (Figure 3A). After the first treatment and
before the second intervention, the scar elevation was
reduced significantly by 18.3% (615.1%) (p = .0143)
compared with baseline. Subsequent documentation
showed a reduction of 29.9% (617.9%) (p = .2258)
after the second, 37.8% (619.9%) (p = .3391) after
the third, and 41.3% (620.6%) (p = .2075) after the
fourth treatment session compared with baseline
(Figure 3B). These results were proportional to the
calculated loss of volume of the scar during treatment
with triamcinolone acetonide injections (Figure 3C).
After the first injection, the average volume was
reduced by 13.1% (610.3%) (p = .017), after the
second by 21.7% (614.0%) (p = .4602), and after the
third injection by 30.5% (616.9%) (p = .5011). By the
fourth visit, the relative decrease of height and volume
was 34.3% (618.0%) (p = .4799) compared with
baseline (Figure 3D).
Sonography
Ultrasound measurements demonstrated a significant
reduction of scar elevation, penetration depth and
TABLE 2. Evaluation of Injected Volumes of
Triamcinolone Acetonide and Absolute




Injected amount of TAC in n = 15
keloids
At Visit I: 10–20 mg/mL Visit I: 0.9 6 0.6 mL
At Visit II: 10–20–40 mg/mL Visit II: 0.9 6 0.7 mL
At Visit III + IV: 20–40 mg/mL Visit III: 0.4 6 0.3 mL
Visit IV: 0.5 6 0.3 mL
Average height 6 SD
Before 3.2 6 1.2 mm
After 2.2 6 1.2 mm
Average volume 6 SD
Before 737 6 417 mm3
After 443 6 345 mm3
Average embossment 6 SD
Before 2.5 6 1.5 mm
After 1.7 6 1.3 mm
Average penetration depth 6 SD
Before 2.0 6 1.3 mm
After 1.4 6 1.2 mm
TAC, triamcinolone acetonide.
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volume, as well as a reduction of echo-poor areas
corresponding to collagen-rich scar tissue (Figure 4A).
As treatment progressed, more echo-rich reflections
became visible in the sonogram indicating a trans-
formation into more homogeneous scar tissue
(Figure 4B). By sonography, a decrease of scar height
(Figure 5A) and intracutaneous infiltration
(Figure 5C) could be demonstrated. After one treat-
ment, an average reduction of scar height of 12.9%
(614.8%) (p = .0134) was observed, after 2 injections
19.8% (615.9%) (p = .0489), after 3 treatments
26.7% (618.6%) (p = .1993), and after 4 injections
31.7% (619.9%) (p = .3992) compared with baseline
(Figure 5B). The reduction in subepidermal depth of
Figure 1. Digital photography of Patient 15 (A and B), Patient 5 (C and D), and Patient 13 (E and F) with keloid before (A, C,
and E) and after (B, D, and F) 4 injections of triamcinolone acetonide in combination with cryotherapy.
Figure 2. The skin-tone and color–height–encoded images were taken with the 3D topographic imaging device PRIMOSpico
using the matching program mode. Patient 2—native scar (A)—was treated 4 times with cryotherapy and triamcinolone
acetonide injections (B).
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the scar after one injection was 15.5% (612.0%)
(p = .0018) and after 2 interventions 25.0% (615.4%)
(p= .1438). An average reductionof 33.2% (617.4%)
(p= .1466) after 3 and of 37.8% (616.7%) (p= .1723)
after 4 injections could be observed (Figure 5D).
Discussion
In this study, the authors aimed to objectively evaluate
treatment success of the guideline-based combina-
tional therapy of cryotherapy and triamcinolone ace-
tonide injections2,14 for the treatment of keloids by
using a 3D topographic imaging device and ultra-
sound. Based on objective measurements, a significant
average reduction of scar volume of 34.3% and an
average decrease in scar height of 41.3% as deter-
mined by 3D imaging was observed after a total of 4
treatment sessions compared with baseline. Ultra-
sound revealed an average reduction of scar height of
31.7% and an average decrease in tissue penetration
depth of 37.8% when compared with baseline meas-
urements. More specifically, 5 of 15 patients reached
an average reduction of scar height and volume of
50% or more after 4 treatment series. An average
reduction between 50% and 20% could be observed
in 5 patients. The remaining 5 patients did not achieve
a sufficient reductionof volumeandheight anddefined
as average reduction by 20% or less after 4 injections
of triamcinolone acetonide combined with cryother-
apy. Based on their observation, a reduction of scar
height by 20% or less after 2 treatment periods con-
stitutes an adequate objective criterion to define
resistance to therapy. Treatments within their study
were tolerated relatively well although intralesional
Figure 3. Absolute reduction of surface height (A) and volume (C) as well as the relative results of the reduction of scar
height (B) and volume (D) as measured with PRIMOSpico.
Figure 4. Ultrasound images of Patient 9 in measuring mode before (A) and after (B) treatment. Clearly visible in the
reduction of embossment and penetration depth. In addition, a decrease of the darker areas before therapy to a more
homogeneous scar tissue after 4 injections of triamcinolone acetonide and cryotherapy is apparent.
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corticosteroid injections have shown side effects in up
to 63% of patients.11 Adverse events in their setting
mostly included formation of telangiectasia (n = 8),
which may be easily improved by pulsed dye lasers or
intense pulsed light.
In depth, assessment of scar therapy is crucial to pre-
vent the implementation of treatment regimen with
a considerable risk of side effects, disproportionate to
the achieved therapeutic success.
Intralesional corticosteroid injections with supple-
mentary cryotherapy are first-line therapy for the
treatment of keloids.2,39 In 1977, the combination of
corticosteroids and cryosurgery was introduced and
detailed information on the method provided.36
Despite the lack of objective parameters, the promis-
ing results led to the establishment of this method.
Injections are recommended for at least 3 courses25 or
until complete flattening of the scar is reached. A
maximum of 8 injections has been proposed.37,40 An
interindividual controlled studywith 10 patients using
calipers and digital photography was performed to
determine the effect of cryotherapy and corticosteroid
injections in keloids.25 A more objective assessment
method was used in a study of 33 patients35: they
took a wax pattern of alginate impressions of each
keloid to observe changes in volume and surface of the
keloids. Patients were treated only once with either
cryotherapy or corticosteroid injections alone or their
combination. The results of combination therapywere
significantly better than either method alone, so the
authors proposed synergistic effect of cryotherapy and
intralesional triamcinolone acetonide. The latest study
on 21 patients was published in 2008 and compared
the therapeutic outcome of either cryotherapy or cor-
ticosteroid injections into the keloid alone with the
combination of both.34 A visual analog scale was used
to evaluate the treatment results, which concluded that
the combination therapy was superior.
Current guidelines for scar therapy2,13 mention
a response rate, which varies between 50% and 100%
and a recurrence rate between 9%and 50%according
to meta-analysis.41–43 These data are based on studies,
which applied different treatment regimens and
diverse evaluation methods—neither objective mea-
surement methods have been applied nor the combi-
nation of cryotherapy and corticosteroid injections
into the keloid has been evaluated. The 4 studies,
which observed the therapy results of corticosteroid
injections alone, were performed in the 1970s or
before.42–45Newer study approaches have not yet been
included in current publications. Also, some studies
did not differentiate between keloids and hypertrophic
scars. As the latter commonly regress spontaneously,2
a definite conclusion about the recurrence rate of
enhanced scar formation cannot be made. The wide
Figure 5. Evaluation of the absolute reduction of scar height (A) and penetration depth (C) measured with high-resolution
B-image sonogram. The authors also observed relative results of the reduction of scar height (B) and penetration depth into
the skin (D).
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fluctuation of response and recurrence rates is not only
due to the various study approaches but also illustrates
that every scar requires an individualized treatment.
A standard approach still does not exist. The updated
international guidelines for scar therapy, therefore,
favor a combination approach with multiple
modalities.46
With modern 3D topographic imaging device height,
volume and surface of the scar can be objectively
documented and compared with a baseline measure-
ment. The 3D topographic imaging devices as the
PRIMOSpico have already provided solid data and
valid results in studies evaluating the therapy of
hypertrophic scars, keloids, acne scars, and striae
distensae.21,26,31,32,38 The various presentation modes
are helpful for the 3-dimensional demonstration of the
treatment progress. The safe and easy handling makes
it a promising tool in clinical scar examination. It is
well-suitable for small to medium scars, but in case of
extended keloid formation, the 3D imaging unit’s field
of view may be too small to capture the entire scar.
Another disadvantage is its inability to measure skin
Types V and VI. As keloids occur more often in Asian
or African individuals9 who present mainly with
darker skin types such as IV to VI according to
Fitzpatrick,47 ultrasound measurement should be
preferred.
Sonography represents a frequently used noninvasive
observation tool in the treatment of pathologic
scars.4,26–29 In dermatological research, high fre-
quency ultrasoundwith 7.5MHz and above is used. It
offers a sufficient penetration depth as well as high
resolution and thereby achieves reliable measurement
results in scar assessment. In contrast to 3D topo-
graphic imaging devices, ultrasound enables the
assessment of scar height and penetration depth but
not of the volume or surface. However, ultrasound is
available in nearly every clinical institution. This
might facilitate its more frequent use compared with
other devices.
Based on their study data, both applied objective
measurement methods can be recommended as highly
suitable for the therapeutic assessment of pathologic
scars. For an overall therapeutic assessment, however,
standardized questionnaires may be helpful by adding
additional relevant parameters to the evaluation33,48,49
because successful scar treatments also include the
reduction of scar-associated symptoms such as pain,
contractures, and pruritus. Established questionnaires
such as the Patient and Observer Scar Assessment
Scale or the Dermatology Life Quality Index cover
important itemsof augmented scar formation andmay
therefore be applied for additional assessment of scar
therapy.1,49
Limitations of their study include the relatively small
number of included patients, the lack of follow-ups,
and certain shortcomings in the standardization of the
injection technique itself.
Conclusion
As corticosteroid injections and cryotherapy are the
mainstay of therapy for hypertrophic scars and
keloids, evaluating the evidence of this treatment
approach is required. Here, the authors could
demonstrate that ultrasound assessment along with
noninvasive in vivo 3D topographic imaging meas-
urements could objectively confirm the clinically
observed efficacy of combined cryotherapy and
intralesional injection of corticosteroids for the
treatment of keloids if the physician is considering
potential side effects such as neovesselfomation and
pigmentary changes.
Because of its sensitivity, these objective measures
may be useful in identifying responders from
nonresponders earlier than conventional assessments
and may thus represent promising tools in future scar
assessments.
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